Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 9,154 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: NDO Full-thickness Plicator; Device
Lead sponsor: NDO Surgical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more

Conditions: Heart Disease
Interventions: SAMe, Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 32
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more

Conditions: Liver Transplant Recipients
Interventions: Cozaar; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: AC2993; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 219
States / cities: Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more

Conditions: Breast Inflammatory Carcinoma
Interventions: Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 214
States / cities: Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more

Conditions: Breast Cancer
Interventions: trastuzumab, carboplatin, paclitaxel; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2019
U.S. locations: 24
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 20 more

Conditions: Gastric Motility
Interventions: Relamorelin, Placebo; Drug
Lead sponsor: Motus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Abdominal Pain
Interventions: Bupivacaine 0.25%, Triamcinolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Magnetic Resonance Imaging (MRI)
Interventions: Blood sample collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimers Disease
Interventions: CNP520 50mg, CNP520 15mg, Matching placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 1,145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 95
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more

Conditions: Atrial Fibrillation, End Stage Renal Disease
Interventions: apixaban, warfarin; Drug
Lead sponsor: Christopher Granger, MD; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 58
States / cities: Huntsville, Alabama • Fresno, California • Long Beach, California + 52 more

Conditions: Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions: Nemtabrutinib; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Palliative Care
Interventions: Palliative care contacts primary care; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 127,070 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: AA Amyloidosis
Interventions: nL-SAA1-01; Drug
Lead sponsor: Nelson Leung, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: capecitabine; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more

Conditions: Heart Failure, Congestive
Interventions: DITPA (3,5-diiodothyropropionic acid), Placebo; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 22
States / cities: Huntsville, Alabama • Peoria, Arizona • Tucson, Arizona + 18 more

Conditions: COVID-19
Interventions: Remdesivir, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 106
States / cities: Anaheim, California • Berkeley, California • Burlingame, California + 76 more

Conditions: Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions: Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more

Conditions: Physiological Stress
Interventions: Lower Body Negative Pressure with Noninvasive Physiological Monitoring; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pain, Cancer, Colonic Diseases
Interventions: GIC-1001; Drug
Lead sponsor: gicare Pharma Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Scottsdale, Arizona • Anaheim, California • Chula Vista, California + 8 more

Conditions: Intensive Care Unit Delirium, Pain, Anxiety, Intensive Care Acquired Cognitive Impairment
Interventions: Slow Tempo Music, Attention Control; Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Avon, Indiana • Indianapolis, Indiana • Rochester, Minnesota

Search by objective public record fields.

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Endoscopic Full-Thickness Plication for the Treatment of GERD: Long-Term Multicenter Results

Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant

Extension Study for 2993-112

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers

Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain

Myocardial Injury in Patients With Cardiac Implantable Electronic Devices Following Magnetic Resonance Imaging

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Non-Invasive EndoPAT Increases Diagnostic Yield of CAD by Coronary Angiography

Impact of Predictive Modeling on Time to Palliative Care in an Outpatient Primary Care Population

Treatment of AA Amyloidosis

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Study of DITPA in Patients With Congestive Heart Failure

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

Lower Body Negative Pressure to Validate Physiological Monitors

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

Decreasing Delirium Through Music in Critically Ill Older Adults